Shebli Atrash
Wake Forest University Health Sciences · Academic and Community Cancer Research United
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shebli Atrash as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:22 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04822337 · Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaWake Forest University Health Sciences · recruiting · Multiple Myeloma · principal investigator
- Ph2NCT04756401 · Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple MyelomaAcademic and Community Cancer Research United · active not recruiting · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph2NCT04230031 · Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple MyelomaWake Forest University Health Sciences · withdrawn · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT03773107 · LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple MyelomaWake Forest University Health Sciences · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2011 to 2026Named on NCT04756401
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:22 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- 61 citationsRCR 1.4
- Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.N Engl J Med · 202644 citationsRCR 22.0
- 17 citationsRCR 3.3
- MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.Blood Adv · 202512 citationsRCR 2.4
- Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.Blood · 20258 citationsRCR 1.4
- A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.Clin Lymphoma Myeloma Leuk · 20236 citationsRCR 0.5
- 3 citationsRCR 0.6